Skip to main content
. 2013 Mar 26;84(12):1400–1403. doi: 10.1136/jnnp-2012-304700

Table 1.

Results and comparisons between those with mobile and those with ‘structural scoliosis’

Patients with Pisa syndrome Mobile scoliosis Structural scoliosis p Value**
Patients 15 3 12
Age (years) 72.1 (5.7, 63.3–82.3) 70.5 72.5 0.6
Male: female 12:3 2:1 10:2 0.5
PD duration (years) 15 (6.1, 7.3–27.3) 15 15 0.99
Deformity duration (years) 5.8 (3, 0.6–13.2) 5.2 5.9 0.7
Daily levodopa LED (mg) 647 (242, 300–1197) 666 642 0.9
Daily dopamine agonist LED (mg) 250 (161, 0–480) 275 244 0.8
Daily PD medication LED (mg) 1010 (330, 498–1697) 1041 1003 0.9
Lateral flexion angle (°) 17.2 (5, 10–25) 18 17 0.6
Standing radiograph Cobb angle (°) 35 (16.4, 8.6–67) 20.8 38.8 0.08
Supine CT Cobb angle (°) 20.4 (12.4, 3.2–45) 6 24.8 <0.01*
Relative collapse scoliosis (%) 44.4 (21.4, 7.8–87.6) 68.7 37.7 0.02*
PDQ-39 total score (0–156) 67 (26, 20–116) 61 68 0.7
WHO well-being index (0–25) 13 (6, 3–25) 15 13 0.6
Fatigue severity scale (0–63) 40 (15, 21–63) 42 40 0.9
Pain visual analogue scale (0–10) 4 (2, 0–8) 3.7 4.1 0.8
MoCA (0–30) 22.6 (4.6, 10–27) 21 25 0.4
FAB (0–18) 12.5 (3.8, 6–18) 11 13 0.4
MDS-UPDRS II 26 (5.6, 20–38) 29 25 0.3
MDS-UPDRS III 43.5 (11.2, 27–61) 50 41 0.2

*Significant difference between groups.

**Group means compared using Student's t test except for gender when Fisher's exact test was used.

No significant differences were found between those with and without a structural scoliosis in terms of PD duration, deformity duration, medication usage, quality of life, pain, cognition or Parkinson's severity (UPDRS II and III). Values given=mean (SD, range).

FAB, frontal assessment battery; LED, Levodopa equivalent dose; MDS-UPDRS, Movement Disorder Society revised Unified Parkinson's Disease Rating Scale; MoCA, Montreal Cognitive Assessment; PD, Parkinson's disease; PDQ, Parkinson's Disease Questionnaire.